Immune Responses in Multiple Hosts to Nucleocapsid Protein (NP) of Crimean-Congo Hemorrhagic Fever Virus (CCHFV)

Overview

Journal PLoS Negl Trop Dis

Specialties Infectious Diseases
Tropical Medicine

Date 2021 Dec 1

PMID 34851958

Citations 11

Authors

Elif Karaaslan

Nesibe Selma Cetin

Merve Kalkan-Yazici

Sevde Hasanoglu

Faruk Karakecili

Aykut Ozdarendeli

Ahmet Kalkan

Ali Osman Kilic

Mehmet Ziya Doymaz

Affiliations

Soon will be listed here.

Abstract

In 2019, the World Health Organization declared 3 billion to be at risk of developing Crimean Congo Hemorrhagic Fever (CCHF). The causative agent of this deadly infection is CCHFV. The data related to the biology and immunology of CCHFV are rather scarce. Due to its indispensable roles in the viral life cycle, NP becomes a logical target for detailed viral immunology studies. In this study, humoral immunity to NP was investigated in CCHF survivors, as well as in immunized mice and rabbits. Abundant antibody response against NP was demonstrated both during natural infection in humans and following experimental immunizations in mice and rabbits. Also, cellular immune responses to recombinant NP (rNP) was detected in multispecies. This study represents the most comprehensive investigation on NP as an inducer of both humoral and cellular immunity in multiple hosts and proves that rNP is an excellent candidate warranting further immunological studies specifically on vaccine investigations.

Citing Articles

The Role of Nucleocapsid Protein (NP) in the Immunology of Crimean-Congo Hemorrhagic Fever Virus (CCHFV).

Pirincal A, Doymaz M Viruses. 2024; 16(10).

PMID: 39459881 PMC: 11512346. DOI: 10.3390/v16101547.

Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21.

Leventhal S, Bisom T, Clift D, Rao D, Meade-White K, Shaia C Nat Commun. 2024; 15(1):9236.

PMID: 39455551 PMC: 11511847. DOI: 10.1038/s41467-024-53362-7.

Cellular immunity to nucleoproteins (NP) of Crimean-Congo hemorrhagic fever virus (CCHFV) and Hazara Virus (HAZV).

Kalkan-Yazici M, Karaaslan E, Guler-Cetin N, Doymaz M Med Microbiol Immunol. 2024; 213(1):20.

PMID: 39320473 DOI: 10.1007/s00430-024-00802-2.

Control strategies for emerging infectious diseases: Crimean-Congo hemorrhagic fever management.

Srivastava S, Kumar S, Sharma P, Rustagi S, Mohanty A, Donovan S Health Sci Rep. 2024; 7(9):e70053.

PMID: 39229478 PMC: 11368823. DOI: 10.1002/hsr2.70053.

Crimean Congo Hemorrhagic Fever Virus for Clinicians-Virology, Pathogenesis, and Pathology.

Frank M, Weaver G, Raabe V Emerg Infect Dis. 2024; 30(5):847-853.

PMID: 38666566 PMC: 11060449. DOI: 10.3201/eid3005.231646.

References

Antrobus R, Coughlan L, Berthoud T, Dicks M, Hill A, Lambe T . Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2013; 22(3):668-674. PMC: 3944330. DOI: 10.1038/mt.2013.284. View

Atkinson R, Burt F, Rybicki E, Meyers A . Plant-produced Crimean-Congo haemorrhagic fever virus nucleoprotein for use in indirect ELISA. J Virol Methods. 2016; 236:170-177. DOI: 10.1016/j.jviromet.2016.07.025. View

Shrivastava N, Shrivastava A, Ninawe S, Sharma S, Kumar J, Alam S . Development of Multispecies Recombinant Nucleoprotein-Based Indirect ELISA for High-Throughput Screening of Crimean-Congo Hemorrhagic Fever Virus-Specific Antibodies. Front Microbiol. 2019; 10:1822. PMC: 6716110. DOI: 10.3389/fmicb.2019.01822. View

Spengler J, Welch S, Scholte F, Coleman-McCray J, Harmon J, Nichol S . Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine. Antiviral Res. 2019; 170:104573. PMC: 6773275. DOI: 10.1016/j.antiviral.2019.104573. View

Saleh M, Nowroozi J, Farahmand B, Fotouhi F . An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge. Biotechnol Lett. 2020; 42(7):1147-1159. DOI: 10.1007/s10529-020-02822-3. View

Dowall S, Carroll M, Hewson R . Development of vaccines against Crimean-Congo haemorrhagic fever virus. Vaccine. 2017; 35(44):6015-6023. PMC: 5637709. DOI: 10.1016/j.vaccine.2017.05.031. View

Guven G, Talan L, Altintas N, Memikoglu K, Yoruk F, Azap A . An Unexpected Fatal CCHF Case and Management of Exposed Health Care Workers. Int J Infect Dis. 2017; 55:118-121. DOI: 10.1016/j.ijid.2016.12.026. View

Saijo M, Qing T, Niikura M, Maeda A, Ikegami T, Prehaud C . Recombinant nucleoprotein-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus. J Clin Microbiol. 2002; 40(5):1587-91. PMC: 130674. DOI: 10.1128/JCM.40.5.1587-1591.2002. View

Yagci-Caglayik D, Kayaaslan B, Yapar D, Kocagul-Celikbas A, Ozkaya-Parlakay A, Emek M . Monitoring Crimean-Congo haemorrhagic fever virus RNA shedding in body secretions and serological status in hospitalised patients, Turkey, 2015. Euro Surveill. 2020; 25(10). PMC: 7078823. DOI: 10.2807/1560-7917.ES.2020.25.10.1900284. View

10.

Baranowska M, Hauge A, Hoornaert C, Bogen B, Grodeland G . Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza. Vaccine. 2015; 33(49):6988-96. DOI: 10.1016/j.vaccine.2015.08.094. View

11.

Andersson I, Bladh L, Mousavi-Jazi M, Magnusson K, Lundkvist A, Haller O . Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J Virol. 2004; 78(8):4323-9. PMC: 374267. DOI: 10.1128/jvi.78.8.4323-4329.2004. View

12.

Ozdarendeli A, Canakoglu N, Berber E, Aydin K, Tonbak S, Ertek M . The complete genome analysis of Crimean-Congo hemorrhagic fever virus isolated in Turkey. Virus Res. 2009; 147(2):288-93. DOI: 10.1016/j.virusres.2009.11.009. View

13.

Farzani T, Foldes K, Hanifehnezhad A, Ilce B, Bilge Dagalp S, Amirzadeh Khiabani N . Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models. Viruses. 2019; 11(3). PMC: 6466008. DOI: 10.3390/v11030237. View

14.

Jeeva S, Pador S, Voss B, Ganaie S, Mir M . Crimean-Congo hemorrhagic fever virus nucleocapsid protein has dual RNA binding modes. PLoS One. 2017; 12(9):e0184935. PMC: 5602631. DOI: 10.1371/journal.pone.0184935. View

15.

Goedhals D, Paweska J, Burt F . Long-lived CD8+ T cell responses following Crimean-Congo haemorrhagic fever virus infection. PLoS Negl Trop Dis. 2017; 11(12):e0006149. PMC: 5752039. DOI: 10.1371/journal.pntd.0006149. View

16.

Wang X, Li B, Guo Y, Shen S, Zhao L, Zhang P . Molecular basis for the formation of ribonucleoprotein complex of Crimean-Congo hemorrhagic fever virus. J Struct Biol. 2016; 196(3):455-465. DOI: 10.1016/j.jsb.2016.09.013. View

17.

Monsalve-Arteaga L, Alonso-Sardon M, Munoz Bellido J, Vicente Santiago M, Vieira Lista M, Lopez Aban J . Seroprevalence of Crimean-Congo hemorrhagic fever in humans in the World Health Organization European region: A systematic review. PLoS Negl Trop Dis. 2020; 14(3):e0008094. PMC: 7067482. DOI: 10.1371/journal.pntd.0008094. View

18.

Wang Y, Dutta S, Karlberg H, Devignot S, Weber F, Hao Q . Structure of Crimean-Congo hemorrhagic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage. J Virol. 2012; 86(22):12294-303. PMC: 3486442. DOI: 10.1128/JVI.01627-12. View

19.

Naderi H, Sheybani F, Bojdi A, Khosravi N, Mostafavi I . Fatal nosocomial spread of Crimean-Congo hemorrhagic fever with very short incubation period. Am J Trop Med Hyg. 2012; 88(3):469-71. PMC: 3592527. DOI: 10.4269/ajtmh.2012.12-0337. View

20.

Mousavi-Jazi M, Karlberg H, Papa A, Christova I, Mirazimi A . Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine. 2012; 30(44):6225-9. DOI: 10.1016/j.vaccine.2012.08.003. View